Bluejay Diagnostics, Inc.
No SEC Form 4 filings for $BJDX in the last 30 days.
See all $BJDX insider activity →Bluejay Diagnostics (BJDX) reported preliminary SYMON-II data from 777 patients, showing ~18% 28-day mortality, to evaluate its Symphony IL-6 test for sepsis. The test is not FDA-cleared, and analyses are ongoing.
Bluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets Partnership Establishes Federal Distribution and Co-Marketing Framework Across VA, DoD, Military Health Systems and Other Government Healthcare
Bluejay Diagnostics (BJDX) partnered with Lovell Government Services for federal healthcare market access, trading at $1.05, up 27.4%. Pharvaris (PHVS) reported 83% attack rate reduction in HAE study, trading at $37.82, up 7.02%. Roivant (ROIV) showed positive Phase 2 results for mosliciguat, trading at $41.35, up 18.35%. Atara Biotherapeutics (ATRA) updated BLA resubmission plans, trading at $10.71, up 9.73%. PDS Biotech (PDSB) raised $22.55M in PIPE financing, trading at $0.29, up 33.21%.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning BJDX (Bluejay Diagnostics, Inc.). Coverage has skewed bullish: 4 bullish, 1 neutral, and 0 bearish.
Recent BJDX coverage spans corporate actions, technology and market movers.
The data suggest the Symphony IL‑6 test may have prognostic value, supporting a path toward FDA 510(k) clearance.
The agreement could unlock a large federal healthcare market, potentially boosting future revenues if FDA clearance is obtained.
Potential revenue boost from exclusive federal distribution.
Stronger liquidity and progress toward an FDA 510(k) are near-term positives, but commercialization timing remains uncertain.
The update reduces clinical execution risk and pairs it with a cash runway extension, supporting a near-term path to 510(k) readiness.
AlphAI scores every news story that mentions BJDX with an AI model for sentiment and relevance, and aggregates insider trades from Bluejay Diagnostics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Bluejay Diagnostics (BJDX) reported preliminary SYMON-II data from 777 patients, showing ~18% 28-day mortality, to evaluate its Symphony IL-6 test for sepsis. The test is not FDA-cleared, and analyses are ongoing.
2 min readBluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets Partnership Establishes Federal Distribution and Co-Marketing Framework Across VA, DoD, Military Health Systems and Other Government Healthcare
2 min readBluejay Diagnostics (BJDX) partnered with Lovell Government Services for federal healthcare market access, trading at $1.05, up 27.4%. Pharvaris (PHVS) reported 83% attack rate reduction in HAE study, trading at $37.82, up 7.02%. Roivant (ROIV) showed positive Phase 2 results for mosliciguat, trading at $41.35, up 18.35%. Atara Biotherapeutics (ATRA) updated BLA resubmission plans, trading at $10.71, up 9.73%. PDS Biotech (PDSB) raised $22.55M in PIPE financing, trading at $0.29, up 33.21%.
3 min readBluejay Diagnostics (BJDX) reported Q2 2026 results with cash and cash equivalents rising to $9.6M from $5.2M at Dec. 31, 2025, an 84% increase, driven by $7.7M net cash from financing including $7.6M from a June private placement. The company completed pivotal enrolment of 750 patients in SYMON-II to support a planned FDA 510(k) for its Symphony IL-6 test.
5 min readBluejay Diagnostics (NASDAQ: BJDX) reported Q2 2026 results and said its SYMON-II pivotal study completed enrollment of 750 patients. The company is progressing toward analytical and clinical validation for a planned FDA 510(k) submission and signed a US manufacturing contract. Cash rose to about $9.6M at June 30, 2026 from $5.2M at Dec. 31, 2025, after a June private placement.
6 min readBluejay Diagnostics (BJDX) said it completed patient enrollment in its pivotal SYMON-II sepsis study, reaching 750 patients ahead of schedule. The multicenter validation evaluates its Symphony IL-6 test for predicting 28-day mortality risk in ICU sepsis patients. The company plans data analysis and expects results to support an FDA 510(k) submission.
2 min readHRT FINANCIAL LP purchased 64,047 shares of Bluejay Diagnostics, Inc. (BJDX) at $1.51 on 2026-07-09.
2 min readBluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ea029420901ex10-1.htm BLUEJAY DIAGNOSTICS, INC. 2021 STOCK PLAN, AS AMENDED BY AMENDMENT NO. 1 THERETO Exhibit 10.1 BLUEJAY DIAGNOSTICS, INC. 2021 STOCK PLAN, AS AMENDED BY AMENDMENT NO.1 THERETO Section 1. Establishment and Purpose. 1.1 The Board of Directors (the “Boa
3 min readBluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 6 ea029339001ex10-1.htm FORM OF SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of June 2, 2026, between Bluejay Diagnostics, Inc., a Delaware corporation (the “ Company ”), and e
6 min readBluejay Diagnostics (NASDAQ: BJDX) said it closed a private placement under Nasdaq rules, selling 3,655,917 shares (or pre-funded warrants) plus Series G and short-term Series H warrants at $2.325 per share. Gross proceeds were $8.5 million, with up to ~$15.2 million more if warrants are fully exercised for cash. The company expects net proceeds to fund operations into Q1 2027.
5 min read
